{"id":"f5b64801b43d","type":"article","url":"https://hartvaat.nl/2026/05/01/cardioselectieve-betablokkers-veilig-en-nuttig-bij-copd-systematische-review/","title":"Cardioselectieve bètablokkers veilig en nuttig bij COPD — systematische review","title_en":"Therapeutic use of cardioselective beta-blockers for patients with chronic obstructive pulmonary disease: a review of current clinical evidence.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Current medical research and opinion","doi":"10.1080/03007995.2026.2692171","source_url":"https://doi.org/10.1080/03007995.2026.2692171","authors":["Elisa Perger","Fabrizio Luppi","Paola Faverio","Laura Pini","Gianfranco Parati"],"significance":6,"published":"2026-08-01","source_date":"2026-05-01","image":"https://hartvaat.nl/global/img/9d6e133ce0bb.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/betablokkers-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/betablokkers-cardiale-indicaties/"],"congress":"","summary_en":"This systematic review evaluates the safety and efficacy of cardioselective beta-blockers (bisoprolol, metoprolol, nebivolol) in patients with COPD and concomitant cardiovascular disease. Contrary to historical concerns about bronchoconstriction, recent trials and meta-analyses demonstrate that cardioselective agents are safe and provide significant cardiovascular benefits without clinically relevant deterioration in lung function. These findings reinforce current guidelines, confirming that cardioselective beta-blockers should be used as first-line therapy in patients with heart failure, coronary artery disease, or hypertension who also have COPD.","created":"2026-07-24T01:05:38Z","updated":"2026-08-10T10:37:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze systematische review analyseert de veiligheid en effectiviteit van cardioselectieve bètablokkers (zoals bisoprolol, metoprolol en nebivolol) bij patiënten met COPD en bijkomende cardiovasculaire aandoeningen. Hoewel er historisch bezorgdheid was over bronchoconstrictie, tonen recente trials en meta-analyses aan dat deze middelen veilig zijn en cardiovasculaire voordelen bieden zonder significante verslechtering van de longfunctie. Voor de klinische praktijk bevestigt dit dat cardioselectieve bètablokkers de eerste keuze blijven bij patiënten met hartfalen, CAD of hypertensie én COPD, mits zorgvuldig getitreerd.","abstract_original":"Cardiovascular diseases, such as hypertension, coronary artery diseases (CAD), arrhythmias, and chronic heart failure (CHF), often require treatment with beta-blockers. These conditions frequently coexist with chronic obstructive pulmonary disease (COPD), which can complicate therapeutic decisions. Indeed, patients with moderate-to-severe COPD are frequently not given these agents out of concern for possible bronchoconstriction arising from blockade of β2-adrenoceptors in the airways. Observational studies, and meta-analyses support the cardiovascular benefits of β-blockade in people with COPD and cardiovascular diseases. Recent trials evaluating cardioselective β-blockade suggest that cardioselective beta-blockers such as bisoprolol, metoprolol and nebivolol are safe and likely beneficial in those patients that would benefit from their intake due to presence of cardiac comorbid diseases. The aim of this systematic review is to summarise the recent trials and indications for use of cardioselective β-blockers in patients with COPD."}